Mark H. Mirochnick, MD

Professor, Pediatrics

Mark Mirochnick

Biography

Mark Mirochnick, MD is Professor of Pediatrics and a member of the Division of Neonatology at Chobanian and Avedisian School of Medicine/Boston Medical Center. His main research activities involve investigating the pharmacology of HIV and TB drugs in newborns, infants, children and pregnant women. He has served as protocol chair, investigator and/or protocol pharmacologist on many international protocol teams in this area. He currently serves as co-chair of the US Perinatal HIV Guidelines Committee and is a member of the US Pediatric HIV Guidelines Committee and the WHO Pediatric Antiretroviral Working Group.

Other Positions

  • Section Director, Neonatology, Pediatrics, Boston University Chobanian & Avedisian School of Medicine

Education

  • University of Vermont College of Medicine, MD
  • Dickinson College, BSc

Publications

  • Published on 1/4/2024

    Bekker A, Yang J, Wang J, Cotton MF, Cababasay M, Wiesner L, Moye J, Browning R, Nakwa FL, Rabie H, Violari A, Mirochnick M, Cressey TR, Capparelli EV. Safety and Pharmacokinetics of Lopinavir/Ritonavir Oral Solution in Preterm and Term Infants Starting Before 3 Months of Age. Pediatr Infect Dis J. 2024 Apr 01; 43(4):355-360. PMID: 38190642.

    Read at: PubMed
  • Published on 12/4/2023

    Persaud D, Bryson Y, Nelson BS, Tierney C, Cotton MF, Coletti A, Jao J, Spector SA, Mirochnick M, Capparelli EV, Costello D, Szewczyk J, Nicodimus N, Stranix-Chibanda L, Kekitiinwa AR, Korutaro V, Reding C, Carrington MN, Majji S, Yin DE, Jean-Philippe P, Chadwick EG. HIV-1 reservoir size after neonatal antiretroviral therapy and the potential to evaluate antiretroviral-therapy-free remission (IMPAACT P1115): a phase 1/2 proof-of-concept study. Lancet HIV. 2024 Jan; 11(1):e20-e30. PMID: 38061376.

    Read at: PubMed
  • Published on 12/1/2023

    Momper JD, Nikanjam M, Best BM, Mirochnick M, Capparelli EV, Cressey TR. Brief Report: Dolutegravir Plasma Protein Binding and Unbound Concentrations During Pregnancy and Postpartum. J Acquir Immune Defic Syndr. 2023 Dec 01; 94(4):332-336. PMID: 37884053.

    Read at: PubMed
  • Published on 10/26/2023

    Van Schalkwyk M, Bekker A, Decloedt E, Wang J, Theron GB, Cotton MF, Eke AC, Cressey TR, Shapiro DE, Bacon K, Knowles K, George K, Browning R, Chakhtoura N, Rungruengthanakit K, Wiesner L, Capparelli EV, Stek AM, Mirochnick M, Best BM. Pharmacokinetics and safety of first-line tuberculosis drugs rifampin, isoniazid, ethambutol, and pyrazinamide during pregnancy and postpartum: results from IMPAACT P1026s. Antimicrob Agents Chemother. 2023 Nov 15; 67(11):e0073723. PMID: 37882552.

    Read at: PubMed
  • Published on 3/1/2023

    Brooks KM, Scarsi KK, Mirochnick M. Antiretrovirals for Human Immunodeficiency Virus Treatment and Prevention in Pregnancy. Obstet Gynecol Clin North Am. 2023 Mar; 50(1):205-218. PMID: 36822704.

    Read at: PubMed
  • Published on 1/26/2023

    Eke AC, Mirochnick M, Lockman S. Antiretroviral Therapy and Adverse Pregnancy Outcomes in People Living with HIV. N Engl J Med. 2023 Jan 26; 388(4):344-356. PMID: 36720135.

    Read at: PubMed
  • Published on 12/18/2022

    Liu XI, Dallmann A, Brooks K, Best BM, Clarke DF, Mirochnick M, van den Anker JN, Capparelli EV, Momper JD. Physiologically-based pharmacokinetic modeling of remdesivir and its metabolites in pregnant women with COVID-19. CPT Pharmacometrics Syst Pharmacol. 2023 Feb; 12(2):148-153. PMID: 36479969.

    Read at: PubMed
  • Published on 12/1/2022

    Coutinho CM, Warshaw MG, Duarte G, Stek A, Violari A, Hofer CB, Deville JG, Ngocho JS, Pilotto JH, Correa MD, Shapiro DE, Fuller TL, Chakhtoura N, Mirochnick M, João EC. Effects of Initiating Raltegravir-Based Versus Efavirenz-Based Antiretroviral Regimens During Pregnancy on Weight Changes and Perinatal Outcomes: NICHD P1081. J Acquir Immune Defic Syndr. 2022 Dec 01; 91(4):403-409. PMID: 36049477.

    Read at: PubMed
  • Published on 11/21/2022

    Abrams EJ, Capparelli E, Ruel T, Mirochnick M. Potential of Long-Acting Products to Transform the Treatment and Prevention of Human Immunodeficiency Virus (HIV) in Infants, Children, and Adolescents. Clin Infect Dis. 2022 Nov 21; 75(Suppl 4):S562-S570. PMID: 36410381.

    Read at: PubMed
  • Published on 9/29/2022

    Béranger A, Bekker A, Solans BP, Cotton MF, Mirochnick M, Violari A, Wang J, Cababasay M, Wiesner L, Browning R, Moye J, Capparelli EV, Savic RM. Influence of NAT2 Genotype and Maturation on Isoniazid Exposure in Low-Birth-Weight and Preterm Infants With or Without Human Immunodeficiency Virus (HIV) Exposure. Clin Infect Dis. 2022 Sep 29; 75(6):1037-1045. PMID: 35134861.

    Read at: PubMed

View 149 more publications: View full profile at BUMC

View all profiles